RxDoctor Payments Data

Carmine Dalto, MD

Pulmonary Disease · Gastonia, NCNPI 1871553131

Payments from drug & device makers

$1,253in general payments, 2019–2025

Across 79 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$350
  • Grifols USA, LLC$192
  • AstraZeneca$139
  • Mylan Specialty L.p.$83
  • Boehringer Ingelheim$82
  • Actelion Pharmaceuticals US, Inc.$71
  • plus $335 from 17 others

What the payments were for

  • Food & beverage$1,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,253 in reported general payments places this provider in the 45th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$51,619
Medicare patients
164
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan20$236,536
OfevNintedanib Esylate14$184,638
Trelegy ElliptaFluticasone/Umeclidin/Vilanter188$151,179
TezspireTezepelumab-Ekko13$49,868
Breo ElliptaFluticasone/Vilanterol55$24,755
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$15,083
SymbicortBudesonide/Formoterol Fumarate47$14,719
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$11,783
EliquisApixaban13$9,045
Spiriva HandihalerTiotropium Bromide12$8,802
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$4,773
Ventolin HfaAlbuterol Sulfate32$2,243
Albuterol Sulfate HfaAlbuterol Sulfate95$2,170
Theophylline ErTheophylline Anhydrous16$1,266
Montelukast Sodium41$262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$71$236,53620 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$350$187,716265 claims
Boehringer IngelheimOfev$82$184,63814 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$139$79,67080 claims
PfizerEliquis$42$9,04513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →